Complete Guide to Chronic Hepatitis B Treatment: Patient Selection, Drug Options, and Duration
This comprehensive review covers HBV treatment strategies including interferon, lamivudine, adefovir, and thymosin alpha-1, with guidance on patient selection and treatment duration for different HBV patient subgroups.
Quick Facts
What This Study Found
Chronic HBV treatment should be individualized based on viral markers, liver status, and patient characteristics, with thymosin alpha-1 offering an immune-enhancing alternative/complement to antiviral drugs across different HBV subgroups.
Key Numbers
How They Did This
Comprehensive clinical review covering treatment indications, drug comparisons, combination strategies, and duration guidelines for all chronic hepatitis B subgroups.
Why This Research Matters
Hepatitis B affects 300 million people. Individualized treatment selection based on patient characteristics optimizes outcomes. Including thymosin alpha-1 in the treatment algorithm expands options.
The Bigger Picture
HBV treatment is not one-size-fits-all. This review established the framework for personalized hepatitis B management that continues to guide clinical practice.
What This Study Doesn't Tell Us
2002 review; treatment landscape has evolved with tenofovir, entecavir, and ongoing cure research. Some treatment recommendations have been updated.
Questions This Raises
- ?Can functional HBV cure be achieved with current or combination therapies?
- ?Should thymosin alpha-1 be standard in HBV treatment algorithms?
- ?How should treatment be individualized for Asian-Pacific populations?
Trust & Context
- Key Stat:
- Personalized treatment HBV treatment should be individualized: different drugs and durations for HBeAg+, HBeAg-, and decompensated patients
- Evidence Grade:
- Moderate to strong evidence from a comprehensive clinical review integrating trial data across multiple treatment options.
- Study Age:
- Published in 2002. While specific drugs have evolved (tenofovir, entecavir now preferred), the personalized treatment approach described remains the framework for current guidelines.
- Original Title:
- Treatment of chronic hepatitis B: case selection and duration of therapy.
- Published In:
- Journal of gastroenterology and hepatology, 17(4), 409-14 (2002)
- Authors:
- Leung, Nancy
- Database ID:
- RPEP-00745
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
How is hepatitis B treated?
Treatment depends on the patient: some need antiviral drugs (lamivudine, now tenofovir/entecavir), some respond to immune boosters (interferon, thymosin alpha-1), and some need combinations. The key is matching treatment to the individual.
Where does thymosin alpha-1 fit?
It's an immune-enhancing option that works differently from antivirals. It's particularly useful for patients who need immune activation rather than just viral suppression, and can be combined with antivirals for enhanced effect.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00745APA
Leung, Nancy. (2002). Treatment of chronic hepatitis B: case selection and duration of therapy.. Journal of gastroenterology and hepatology, 17(4), 409-14.
MLA
Leung, Nancy. "Treatment of chronic hepatitis B: case selection and duration of therapy.." Journal of gastroenterology and hepatology, 2002.
RethinkPeptides
RethinkPeptides Research Database. "Treatment of chronic hepatitis B: case selection and duratio..." RPEP-00745. Retrieved from https://rethinkpeptides.com/research/leung-2002-treatment-of-chronic-hepatitis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.